PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.

Authors

Johann S. De Bono

The Institute of Cancer Research and Royal Marsden, London, United Kingdom

Johann S. De Bono , Karim Fizazi , Fred Saad , Neal D. Shore , Guilhem Roubaud , Mustafa Ozguroglu , Nicolas Penel , Nobuaki Matsubara , Niven Mehra , Giuseppe Procopio , Michael Paul Kolinsky , Kazuo Nishimura , Susan Feyerabend , Jae Young Joung , Nicholas J. Vogelzang , Michael Anthony Carducci , Jinyu Kang , Christian Heinrich Poehlein , Wenting Wu , Maha H. A. Hussain

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02987543

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 134)

Abstract #

134

Poster Bd #

F14

Abstract Disclosures

FEATURED

PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.

Authors

Johann S. De Bono

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.